Blood Transfusion Diagnostics Market Size, Share & Trends Analysis Report By Product (Reagents & Kits, Instruments), By Application, By End Use (Hospitals, Diagnostic Laboratories), By Region, And Segment Forecasts, 2021 - 2027

Report Overview

The global blood transfusion diagnostics market size was valued at USD 3,713.7 million in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 6.6% from 2021 to 2027. This growth can be attributed to the increasing rate of approval by the U.S. FDA for blood transfusion diagnostics products. The introduction of new technologies to assist in blood donation and storage is expected to further drive the market.

The rising prevalence of chronic and infectious diseases such as severe anemia, cancer, hemophilia, kidney disease, liver disease, severe infection, sickle cell disease, and thrombocytopenia and the introduction of technologically advanced products are among the factors driving the demand for blood transfusion. According to the National Heart, Lung, and Blood Institute, anemia is one of the most common blood-related disorders and affects over 3 million people in the U.S. majority of the cases are due to iron deficiency.

There is an increasing risk of Transfusion-transmitted Infections (TTIs) that has led to high demand for donor screening. To prevent patients from unsuitable blood and blood products and combat TTIs, the need for donor screening is increasing. Numerous countries, including the UAE, South Africa, and the U.S., have made TTI testing a mandatory protocol. Thus, factors such as the rising number of TTI cases and lack of awareness among affected donors about their diseases are expected to drive the market for blood transfusion diagnostics to a great extent.

A rise in the number of trauma, road accidents, surgeries, and childbirth cases has also led to significant transfusions, thus, driving the market. According to CDC, every year an average of around 6 million car accident cases occur in the U.S. Among them, approximately 3 million people are injured. Globally, around 50 million road traffic injuries occur each year according to the WHO 2018 report. Moreover, surgeries such as post-cardiopulmonary bypass, neurosurgery, posterior eye surgery, and chronic bleeding disorders also require platelet transfusions.

Growing initiatives for blood donation campaigns is another driver boosting market growth significantly. The slogan for the 2021 was Give blood and keep the world-beating. The major focus of this year’s campaign by WHO was to encourage the young population to donate and ensure a safe blood supply. With economies are relaxing their norms and the number of blood donation campaigns across the world is increasing, the need for blood transfusion diagnostics is expected to increase to the pre-COVID-19 level. For instance, e-RaktKash, a blood collection organization in India, has planned approximately 53 campaigns across India from October 2021 to March 2022.

Product Insights

In 2020, the reagents and kits segment dominated the market for blood transfusion diagnostics and accounted for the largest revenue share of 65.8%. Easy availability of products and repetitive purchase of these products required to screen both donor and recipient samples have majorly driven the segment growth. In addition, the availability of a wide variety of blood grouping, typing, and donor screening reagents, kits, and assays manufactured by both global and local players is another factor driving the segmental growth.

The availability of technologically advanced donor screening analyzers has led to the lucrative growth of this segment. For instance, MosaiQ by Quotient is a fully automated platform to conduct blood grouping and TTI screening of donor samples. In addition, the rising availability of rapid diagnostic kits for safe blood transfusion is expected to propel market growth in the coming years.

Increasing the launch of products and approvals for different systems or automated systems by key players for blood transfusion is expected to boost the market growth. For instance, in April 2021, Ortho Clinical Diagnostics launched ORTHO VISION Swift and ORTHO VISION Max Swift analyzers. These analyzers offer more processing power and advanced data security to laboratory networks.

Application Insights

The disease screening segment dominated the market for blood transfusion diagnostics and accounted for the largest revenue share of 60.0% in 2020. This can be attributed to a high number of transfusion-transmitted infection cases; increasing safety screening of donated blood, to maintain safe transfusion; rising technological advancements; and wide product portfolios offered by key players in the market.

Furthermore, the growing focus of various research studies on performing experiments with serological testing approaches is expected to be a driving factor for the segment. For instance, a research study published in Nature Communication in 2021 reviewed the SARS-CoV-2 antibody seroprevalence among blood donors in the Chinese cities of Wuhan, Shenzhen, and Shijiazhuang. Such studies would increase the demand for blood transfusion diagnostics products.

The blood grouping segment is expected to hold a significant revenue share during the study period. These diagnostic tests are commonly performed in the blood banks. Routine blood typing and cross-matching tests performed before transfusion therapy for identifying the compatibility of donor and recipient blood are some of the factors driving the segmental growth.

End-use Insights

The blood banks segment dominated the market for blood transfusion diagnostics and accounted for the largest revenue share of 38.9% in 2020. This is due to a large number of disease screening and blood typing services performed before transfusion therapy. These facilities are increasingly maintaining the safety of blood supply through thorough disease screening while complying with the regulatory standards. Some of the standard tests performed in these end-use settings with the donated blood include blood typing, Rh typing, unexpected RBC antibody screening, and infectious disease screening.

More than 10.0% of hospitalized patients require transfusion. This rate is higher in emergency rooms, wherein accident victims are frequently admitted. It is mandatory for hospitals to screen donated blood for infections, perform compatibility tests of donor and recipient as a pretransfusion therapy, and set parameters of hematology components. Thus, the hospitals' segment accounted for significant shares in 2020.

Regional Insights

North America dominated the blood transfusion diagnostics market and accounted for the largest revenue share of 40.1% in 2020. The segment is expected to maintain its position during the forecast period. Increasing health awareness, high disposable income, favorable reimbursement policies, and well-established healthcare infrastructure are some of the key factors boosting the regional market. According to Community Blood Center data, every day around 43,000 pints of donated blood is used in both the U.S. and Canada.

The U.S. accounted for the leading share in North America. Key factors contributing to its dominance include the local presence of major market players, easy availability of various assays for testing, and over 600 independent donation facilities. Independent blood centers collect over 60% of blood donations in the U.S. and are responsible for 25% of the Canadian blood collection supply.

In Asia Pacific, the market for blood transfusion diagnostics is expected to grow at the fastest rate during the forecast period. Increasing awareness about blood donations coupled with the launch of various campaigns in India and Australia is fostering regional growth. However, the declining number of donors in Singapore and South Korea has led to less adoption of transfusion diagnostic tools in Asia Pacific.

Key Companies & Market Share Insights

The market is gaining considerable attention from several companies and regulatory authorities. Companies in this market are continuously undertaking various strategic initiatives to accelerate the development and manufacture of diagnostic tests for blood in turn gaining a competitive edge over others.

For instance, in September 2021, Hemanext, a blood storage tech developer, announced to raise USD 15 million funds via new series A funding round and USD 100 million from private equity. It aims to expand the Hemanext One System processes across the globe. The technology received a CE mark and is permitted to be sold in Europe. Some of the prominent players in the blood transfusion diagnostics market include:

• Immucor, Inc.

• Ortho Clinical Diagnostics

• Abbott

• Bio-Rad Laboratories

• F. Hoffmann-La Roche AG

• Quotient Limited

• BAG Healthcare GmbH

• DiaSorin S.P.A.

• Danaher

• BIOKIT (Werfen)

Blood Transfusion Diagnostics Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2027. For the purpose of this study, Grand View Research has segmented the global blood transfusion diagnostics market report on the basis of product, application, end use, and region:

• Product Outlook (Revenue, USD Million, 2016 - 2027)

  • Reagents & Kits

  • Instruments

  • Others

• Application Outlook (Revenue, USD Million, 2016 - 2027)

  • Blood Grouping

  • Disease Screening

    • Serological Disease Screening

    • Molecular Disease Screening

• End-use Outlook (Revenue, USD Million, 2016 - 2027)

  • Hospitals

  • Blood Banks

  • Diagnostic Laboratories

  • Others

• Regional Outlook (Revenue, USD Million, 2016 - 2027)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • Spain

    • France

    • Italy

    • Russia

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Singapore

    • Australia

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • MEA

    • South Africa

    • Saudi Arabia

    • UAE